High Prevalence of Cryptococcal Antigenemia among HIV-infected Patients Receiving Antiretroviral Therapy in Ethiopia

Abere Shiferaw Alemu, Haramya University, Ethiopia
Russell Ryan Kempker, Emory University
Admasu Tenna, Addis Ababa University, Ethiopia
Christopher Smitson, Emory University
Nega Berhe, Addis Ababa University, Ethiopia
Daniel Fekade, Addis Ababa University, Ethiopia
Henry Michael Blumberg, Emory University
Abraham Aseffa, Armauer Hansen Research Institute, Ethiopia

Journal Title: PLoS ONE
Volume: Volume 8, Number 3
Publisher: Public Library of Science | 2013-03-04, Pages e58377-e58377
Type of Work: Article | Final Publisher PDF
Publisher DOI: 10.1371/journal.pone.0058377
Permanent URL: http://pid.emory.edu/ark:/25593/f7hgd

Final published version:
http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0058377

Copyright information:
© 2013 Alemu et al.
This is an Open Access work distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/).

Accessed April 23, 2020 2:02 AM EDT
High Prevalence of Cryptococcal Antigenemia among HIV-infected Patients Receiving Antiretroviral Therapy in Ethiopia

Abere Shiferaw Alemu1*, Russell R. Kempker2*, Admasu Tenna3, Christopher Smitson2, Nega Berhe4, Daniel Fekade3, Henry M. Blumberg2,5, Abraham Aseffa6

1 Haramaya University, Medical Laboratory Technology, Harar, Ethiopia, 2 Division of Infectious Diseases Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, United States of America, 3 Division of Infectious Diseases, Department of Medicine, Addis Ababa University, Addis Ababa, Ethiopia, 4 Akilu Lemma Institute of Pathobiology, Addis Ababa University, Addis Ababa, Ethiopia, 5 Departments of Epidemiology and Global Health, Rollins School of Public Health of Emory University, Atlanta, Georgia, United States of America, 6 Armauer Hansen Research Institute, Addis Ababa, Ethiopia

Abstract

Background: Cryptococcal disease is estimated to be responsible for significant mortality in Sub-Saharan Africa; however, only scarce epidemiology data exists. We sought to evaluate the prevalence of and risk factors for cryptococcal antigenemia in Ethiopia.

Methods: Consecutive adult HIV-infected patients from two public HIV clinics in Addis Ababa, Ethiopia were enrolled into the study. A CD4 count ≤ 200 cells/µl was required for study participation. Patients receiving anti-retroviral therapy (ART) were not excluded. A cryptococcal antigen test was performed for all patients along with an interview, physical exam, and medical chart abstraction. Logistic regression analysis was used to assess risk factors for cryptococcal antigenemia.

Results: 369 HIV-infected patients were enrolled; mean CD4 123 cells/µl and 74% receiving ART. The overall prevalence of cryptococcal antigenemia was 8.4%; 11% in patients with a CD4 count < 100 cells/µl, 8.9% with CD4 100 to 150 cells/µl and 5.7% with CD4150-200 cell/µl. 84% of patients with cryptococcal antigenemia were receiving ART. In multivariable analysis, increasing age, self reported fever, CD4 count < 100 cells/µl, and site of screening were associated with an increased risk of cryptococcal antigenemia. No individual or combination of clinical symptoms had optimal sensitivity or specificity for cryptococcal antigenemia.

Conclusion: Cryptococcal antigenemia is high in Ethiopia and rapid scale up of screening programs is needed. Screening should be implemented for HIV-infected patients with low CD4 counts regardless of symptoms or receipt of ART. Further study into the effect of location and environment on cryptococcal disease is warranted.

Introduction

Increasing access to antiretroviral therapy (ART) has transformed the prognosis of HIV-infected patients in resource-limited settings. However, treatment coverage remains relatively low, and HIV diagnosis occurs at a late stage [1]. The high burden of opportunistic infections remains an enormous challenge to optimal HIV care and in resource-limited settings (RLS), patients continue to die of HIV-related opportunistic infections (OIs) in the weeks prior to, and months following initiation of ART. In particular, recent reports highlight the alarming issue of cryptococcal meningitis (CM) in Sub-Saharan Africa (SSA) and make it clear that there is still much to be done to improve the diagnosis and management of CM [2,3]. Although data is limited on the prevalence of CM in much of SSA, it is estimated there are > 700,000 cases of CM in SSA annually resulting in > 500,000 deaths [2]. The high case fatality rate is due in large part to the lack of diagnostics and appropriate treatment options in RLS. The tragic situation of CM in SSA and other resource-limited settings presents a tremendous opportunity for various stakeholders to work together to confront the emerging CM epidemic.

The World Health Organization (WHO) has recently released “rapid advice” guidelines for cryptococcal disease among persons living with HIV which are focused on RLS [1]. Early diagnosis is key to reducing mortality due to cryptococcal disease. A major WHO recommendation is to consider implementation of cryptococcal antigen screening and pre-emptive anti-fungal therapy in those with a positive diagnostic test among ART-naive adults with a CD4 count < 100 cell/µl in areas with a high prevalence of cryptococcal disease. The recommendation is supported by epidemiological and clinical studies demonstrating a high preva-
vidence of cryptococcal antigenemia among ART-naıve adults in several RLS, [4–7] increased one-year mortality in patients with cryptococcal antigenemia, [4,3] and the cost effectiveness of screening and treatment of HIV-infected patients with cryptococcal antigenemia [9]. Additionally, data demonstrating cryptococcal antigenemia may precede the development of CM by up to 22 days add to the scientific rationale of a screen and treat strategy [9].

One limitation to implementing the WHO guidelines is that the prevalence of cryptococcal infection is not known in many countries in SSA, related in large part to lack of diagnostic capacity for cryptococcus and other HIV-related OIs. The purpose of our study was to determine the prevalence of and risk factors for cryptococcal antigenemia among HIV-infected adults attending two large public HIV clinics in Addis Ababa, Ethiopia. Currently no data exists on the extent of cryptococcal infection in Ethiopia, the second largest country in Africa with an estimated 1.1 million persons living with HIV [10]. An improved understanding of the epidemiology of cryptococcal infection is important in designing, studying, and implementing effective cryptococcal intervention strategies in Ethiopia and other similar countries in SSA.

Methods

Study Design and Patients

We performed a cross sectional study among HIV-infected patients in Addis Ababa, Ethiopia attending two large public HIV clinics. Consecutive patients were enrolled between May and August 2011 from the outpatient ART clinics of both Tikur Anbessa (Black Lion) Hospital and ALERT hospital, which have over 1,000 and 6,000 registered HIV-infected patients, respectively. Patients ≥18 years old and with a CD4 count ≤200 cells/µl were enrolled during a routine clinic visit. Study participants were not required to be ART naıve. Patients treated for cryptococcal infection in the last three months or currently taking antifungal agent were excluded from study participation.

Ethics Statement

The study was conducted according to the principles of the Declaration of Helsinki. Written informed consent was required from all study participants and the study was approved by the Institutional Review Boards of Emory University, Addis Ababa University, and Armauer Hansen Research Institute (AHRI)/ALERT Hospital. All samples were de-identified of personal identifiers for data entry and data analysis.

Procedures

Patient interview, a physical exam, and medical chart review and abstraction were performed for each study participant to collect information regarding demographics, medical history, and clinical signs and symptoms. Specific information from the medical chart was collected on ART use, opportunistic infection history, and the most recent CD4 count.

A blood sample was obtained from each study participant to perform cryptococcal antigen testing using the Meridian Cryptococcal Latex Agglutination System (Meridian Bioscience, Cincinnati, OH, USA), a simple FDA-approved latex agglutination test capable of detecting the capsular polysaccharide of Cryptococcus neoformans in blood. Serum was separated from the blood sample and then frozen at –20°C. Serum samples were batched and cryptococcal antigen testing was performed every 5–7 days at the Armauer Hansen Research Institute (AHRI) laboratory according to the manufacturer’s recommendation. In brief, 200 µl of thawed serum sample was added to 200 µl of pronase solution, incubated at 36°C for 15 minutes, and then boiled for 5 minutes. After cooling, 25 µl of the specimen was placed on an agglutination card along with one drop of detection latex and then the card was shaken to mix the contents together. Positive and negative controls were also included. Results were read out visually based on degree of agglutination and rated on a scale ranging from 0 to 4+. A reading of 2+ was considered positive. For all positive samples, specimens were further tested after serial dilutions from 1:4 up to 1:1024. The same laboratory technician performed all cryptococcal antigen latex agglutination testing. All test results were communicated to each patient’s physician.

Data Analysis

All data was entered into an online REDCap database [11] and analyzed using SAS version 9.3 (SAS institute, Cary, NC, USA). For comparing characteristics among patients with a positive or negative cryptococcal antigen test result, differences in categorical variables were tested using χ² and for continuous variables a two-sample t-test was performed. Univariate and multivariate logistic regression analyses were performed to assess risk factors for a positive cryptococcal antigen test result. Risk factors with possible significance or those with biologic plausibility and known to be associated with cryptococcal disease were included in the model. Model building and selection was based on the purposeful selection of covariates strategy as previously described [12]. The sensitivity, specificity, negative and positive predictive value, and overall accuracy of certain risk factors were calculated. A p value <0.05 was considered statistically significant.

Results

Patients and antigen screening

A total of 369 HIV-infected patients in Addis Ababa were enrolled into the study (Table 1). The mean age of those enrolled was 36 years and 56% were female. The majority of patients were being prescribed ART (74%) and had been receiving ART for a mean duration of 34 months. The mean CD4 count was 123 cells/µl and 31% had a CD4 count less than 100 cells/µl. Over 70% of patients were enrolled from site 1 (ALERT). Only two patients had a prior history of cryptococcal disease (1%) in contrast to a high prevalence of prior pulmonary (25%) and extra pulmonary tuberculosis (9%). At least one clinical symptom was reported by 46% of patients with headache (28%) being the most common followed by fever (22%), night sweats (20%), and cough (18%). A total of 51 patients (14%) had a temperature ≥38.3°C recorded at the study visit.

Among the 369 HIV-infected patients enrolled, 31 (8.4%) had a positive cryptococcal antigen test and all titers were 1:8 or greater (Table 1). When stratified by CD4 count, 11% of patients with a CD4 <100 cells/µl had a positive cryptococcal antigen test as compared to 8.9% with CD4 between 100 to 150 cells/µl and 5.7% with CD4 >150 cell/µl (Figure 1). The large majority of patients with a positive cryptococcal antigen test (84%) were receiving ART. None of the patients with a positive cryptococcal antigen test had a known history of cryptococcal disease.

Comparison of positive and negative antigen patients

Patients with a positive cryptococcal antigen test were significantly more likely to be older (40 vs. 36 years) and male (61% vs. 43%) as compared to those with a negative test. Patients with a positive cryptococcal antigen test were also much more likely to receive care at Site 1 [ALERT] (OR = 4.05, 95% CI 1.20–13.63).
Patients with cryptococcal disease had a higher prevalence of fever than those with a negative test for cryptococcal disease but the difference did not reach statistical significance in univariate analysis (11/31 [36%] vs. 69/338 [21%], OR = 2.14, 95% CI 0.98–4.67, p = 0.06). In univariate analysis, there were no significant differences between those with and without a positive diagnostic test for cryptococcal disease for duration of HIV infection, receipt of ART, CD4 count status, and current or history of opportunistic infections and clinical symptoms and signs (Table 2).

Table 1. Baseline Characteristics of all 369 patients and comparison by cryptococcal antigen status.

| Characteristic                  | Total (n = 369) | CRAG positive (n = 31) | CRAG negative (n = 338) | P* |
|---------------------------------|----------------|-----------------------|-------------------------|----|
| Mean Age in years, (IQR)       | 36 (30–41)     | 40                    | 36                      | 0.02 |
| Male (%)                        | 163 (44)       | 19 (61)               | 144 (43)                | 0.05 |
| Site 1 vs. 2 (%)                | 263 (72)       | 28 (90)               | 235 (70)                | 0.02 |
| BMI <18.5 kg/m² (%)             | 98 (27)        | 4 (13)                | 94 (28)                 | 0.07 |
| Mean months HIV diagnosis (IQR)| 33 (5–59)      | 36                    | 33                      | 0.55 |
| Taking ART (%)                  | 271 (74)       | 26 (84)               | 245 (73)                | 0.19 |
| Mean months on ART (IQR), n = 262| 34 (8–58)     | 37                    | 33                      | 0.56 |
| Mean CD4 count (IQR)            | 123 (82–167)   | 110                   | 124                     | 0.14 |
| CD4 count status (%)            |                |                       |                         |     |
| <100                            | 116 (31)       | 13 (42)               | 103 (31)                | 0.28*|
| 100–150                         | 113 (31)       | 10 (32)               | 103 (31)                |     |
| 151–2000                        | 140 (38)       | 8 (26)                | 132 (39)                |     |
| History of OIs (%)              |                |                       |                         |     |
| Cryptococcal disease            | 2 (1)          | 0                     | 2 (1)                   | 0.67 |
| Pulmonary TB                    | 91 (25)        | 11 (36)               | 80 (24)                 | 0.14 |
| Herpes Zoster                   | 33 (9)         | 1 (3)                 | 32 (10)                 | 0.24 |
| Current OIs (%)                 |                |                       |                         |     |
| Pulmonary TB                    | 24 (7)         | 2 (7)                 | 22 (7)                  | 0.99 |
| Pneumonia or URI                | 9 (2)          | 0                     | 9 (3)                   | 0.36 |
| Current Symptoms* (%)           |                |                       |                         |     |
| No symptoms                     | 196 (54)       | 14 (48)               | 182 (56)                | 0.42 |
| Fever                           | 80 (22)        | 11 (38)               | 69 (21)                 | 0.053|
| Headache                        | 104 (28)       | 9 (29)                | 95 (28)                 | 0.92 |
| Neck Stiffness                  | 11 (3)         | 2 (7)                 | 9 (3)                   | 0.24 |
| Altered Mental Status           | 17 (5)         | 2 (7)                 | 15 (4)                  | 0.61 |
| Photophobia                     | 26 (7)         | 3 (10)                | 23 (7)                  | 0.55 |
| Nausea                          | 44 (12)        | 6 (19)                | 38 (11)                 | 0.18 |
| Night sweats                    | 72 (20)        | 7 (23)                | 65 (19)                 | 0.65 |
| Cough                           | 65 (18)        | 6 (19)                | 59 (18)                 | 0.80 |
| Vomiting                        | 31 (9)         | 4 (13)                | 27 (8)                  | 0.35 |
| Shortness of breath             | 29 (8)         | 0                     | 29 (9)                  | 0.09 |
| Signs (%)                       |                |                       |                         |     |
| Meningismus                     | 4 (1)          | 1 (3)                 | 3 (1)                   | 0.23 |
| Skin papules                    | 15 (4)         | 0                     | 15 (5)                  | 0.23 |
| Fever (≥38.3°C)                 | 51 (14)        | 5 (16)                | 46 (14)                 | 0.70 |
| Cryptococcal antigen titer (%)  |                |                       |                         |     |
| 1:8                             | -              | 5 (16)                | -                       |     |
| 1:16                            | -              | 8 (25)                | -                       |     |
| 1:32                            | -              | 9 (29)                | -                       |     |
| 1:64                            | -              | 3 (10)                | -                       |     |
| 1:128                           | -              | 3 (10)                | -                       |     |
| 1:1024                          | -              | 3 (10)                | -                       |     |

*Based on patient self-report; CRAG, serum cryptococcal antigen; BMI, body mass index; ART, antiretroviral therapy; OI, opportunistic infection; TB, tuberculosis; URI, upper respiratory infection acid; *ANOVA Statistic.
doi:10.1371/journal.pone.0058377.t001
Cryptococcal Antigen Screening

Risk factors for a positive cryptococcal antigen test in multivariate analysis

In multivariate analysis, increasing age (aOR 1.05, 95% CI 1.002–1.09), clinic site 1 vs. 2 (aOR 5.49, 95% CI 1.57–19.16), fever (aOR 2.81, 95% CI 1.06–7.47) were all significantly associated with an increased risk of cryptococcal antigenemia (Table 2). Conversely, a BMI <18.5 kg/m² was associated with a decreased risk of a cryptococcal antigenemia (aOR 0.32, 95% CI 0.10–0.98).

Clinical symptoms and antigenemia

Results of an analysis of the performance of individual and combinations of four candidate symptoms in detecting cryptococcal antigenemia including negative and positive predictive value are shown in Table 3. There was poor sensitivity of any one symptom (10–36%) or combination of symptoms (9–43%) in detecting cryptococcal antigenemia. We also found less than optimal specificity of individual (72–93%) or combinations of symptoms (62–97%) for cryptococcal antigenemia.

Discussion

Our study demonstrates a high prevalence of cryptococcal antigenemia among HIV-infected adults attending ART clinics in Addis Ababa, Ethiopia. Criteria for study entry was a CD4 count of ≤200 cells/µl; the overall prevalence of cryptococcal antigenemia was 8.4% and among patients with CD4 counts ≤100 cells/µl, the prevalence exceeded 11%. In multivariate analysis, increasing age, self reported fever, site of screening, and lower CD4 count (<100 cells/µl) were associated with an increased risk of having a positive serum cryptococcal antigen test.

These data are the first to describe the prevalence of cryptococcal antigenemia among HIV-infected patients in Ethiopia in the HAART era. The high prevalence of cryptococcal subclinical infection highlights the need for implementation of routine cryptococcal antigen screening in Ethiopia among HIV-infected persons. Current WHO guidelines recommend consideration of cryptococcal screening in high prevalence RLS among those with CD4<100 cells/µl and not on ART (followed by pre-emptive anti-fungal therapy if cryptococcal antigen positive) [1]. In contrast to prior studies done outside Ethiopia in Sub-Saharan Africa, [4,8] we found a high prevalence of cryptococcal antigenemia (7.1%) among patients with CD4 counts between 100–200 cells/µl, which calls into question whether screening recommendations should be expanded to include patients with CD4 counts <200 cells/µl. We also found a previously unreported high prevalence of cryptococcal antigenemia among patients receiving ART and a significant effect of location on prevalence rates, results that may have implications for developing optimal cryptococcal screening prevention and treatment strategies. While our study found a CD4 count ≤100 cells/µl was significantly associated with cryptococcal antigenemia in multivariate analysis, the majority of positive patients (58%) in our study had a CD4 count between 100–200 cells/µl. Additionally, our prevalence rate of cryptococcal antigenemia (7.1%) in patients with a CD4 count >100 cells/µl was in contradiction to lower prevalence rates among patients with CD4 counts >100 cells/µl in South Africa (1.1%) 4, Uganda (2.7%) 9, and Thailand (3.6%) 7. One reason we may have found a high prevalence of cryptococcal antigenemia among persons with a CD4 >100 is our inclusion of patients already on ART. These patients could have developed infection at lower CD4 counts, leading to higher prevalence rates among patients with CD4 counts >100 cells/µl.

Table 2. Univariate and multivariate analysis of risk factors for cryptococcal antigenemia among HIV infected patients in Addis Ababa, Ethiopia (n = 369).

| Characteristic | Univariate Analysis | Multivariate Analysis |
|---------------|---------------------|----------------------|
|               | OR (95% CI)         | P        | OR (95% CI) | P        |
| Age, per year | 1.05 (1.01–1.09)    | 0.02     | 1.05 (1.002–1.09) | 0.04    |
| Male          | 2.12 (1.00–4.51)    | 0.05     |             |          |
| Site 1 vs. 2  | 4.05 (1.20–13.63)   | 0.02     | 5.49 (1.57–19.16) | 0.01    |
| BMI <18.5 kg/m² | 0.39 (0.13–1.13)   | 0.08     | 0.32 (0.10–0.98) | 0.046   |
| Currently employed | 1.33 (0.62–2.87) | 0.46 |             |          |
| On ART        | 1.91 (0.71–5.10)    | 0.20     | 2.60 (0.91–7.45) | 0.08    |
| CD4 count status |                      |          |             |          |
| <100          | 2.08 (0.83–5.21)    | 0.34     | 2.81 (1.06–7.47) | 0.04    |
| 100–150       | 1.60 (0.61–4.20)    | 0.11     | 1.81 (0.65–5.04) | 0.26    |
| 151–200       | 1.00                |          | 1.00        |          |
| Past OIs      |                     |          |             |          |
| TB            | 1.16 (0.54–2.50)    | 0.71     |             |          |
| Herpes Zoster | 1.40 (0.40–4.95)    | 0.60     |             |          |
| Current OIs (%)|                    |          |             |          |
| TB            | 0.71 (0.16–3.16)    | 0.65     |             |          |
| Symptoms      |                     |          |             |          |
| Fever (≥38.3°C) | 1.22 (0.45–3.33) | 0.70 |             |          |
| Photophobia   | 1.46 (0.41–5.18)    | 0.56     |             |          |
| Signs         |                     |          |             |          |
| Meningismus   | 3.71 (0.37–36.79)   | 0.27     |             |          |

BMI, body mass index; ART, antiretroviral therapy; OI, opportunistic infection; TB, tuberculosis.

doi:10.1371/journal.pone.0058377.t002

Figure 1. Percentage of HIV infected patients with cryptococcal antigenemia by CD4 count and antiretroviral use.
doi:10.1371/journal.pone.0058377.g001
Cryptococcal Antigen Screening

Table 3. Predicting cryptococcal antigenemia based on the presence of individual or combination of clinical symptoms (n = 369).

| Symptom(s)                          | Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) |
|-------------------------------------|-----------------|-----------------|---------|---------|
| Fever                               | 36              | 80              | 14      | 93      |
| Headache                            | 29              | 72              | 9       | 92      |
| Photophobia                         | 10              | 93              | 12      | 92      |
| Night Sweats                        | 23              | 81              | 10      | 92      |
| Fever, Headache, or Photophobia     | 42              | 62              | 10      | 92      |
| Fever, Headache, and Photophobia    | 9               | 97              | 3       | 92      |

PPV, positive predictive value; NPV, negative predictive value.
doi:10.1371/journal.pone.0058377.t003

antigen test were receiving ART and had been receiving for a mean duration of 37 months. Unfortunately, no data on HIV viral load was available on these patients and there was no way to assess if patients were responding appropriately to their ART regimen. While this may limit the generalization of our results, the current situation in SSA usually precludes healthcare providers from determining ART treatment failure thus making it difficult to base screening recommendations on ART response.

Our study adds to the mounting evidence for the public health importance of screening for cryptococcal antigenemia among HIV-infected adults in SSA and other RLS. Our overall prevalence of cryptococcal antigenemia (8.4%) is in line with results from Uganda (5–9%), South Africa (13%), and Kenya (6%) and reaffirms that in SSA high rates of cryptococcal disease are usually found when looked for. However, compared to tuberculosis (TB) prevalence, there are limited data on the magnitude of cryptococcal infection in SSA even though cryptococcal and TB disease have been estimated to be responsible for a similar mortality among HIV infected patients in SSA [2]. Our study is the first to estimate the prevalence of cryptococcal antigenemia in Ethiopia. Given Ethiopia has an estimated 1.1 million people living with HIV, the potential enormity of cryptococcal infection based on our results is significant and argues for rapid scale up of cryptococcal antigen screening among HIV-infected persons.

Further large-scale studies of cryptococcal infection are currently underway in South Africa and are needed in other SSA and RLS countries to better understand the true extent of disease burden. Scale up of screening may be enhanced by the introduction of a FDA-approved cryptococcal antigen point of care test that has a high sensitivity and specificity [13,14].

Our finding in multivariate logistic regression, after controlling for ART use and CD4 count, that patients at site 1 as compared to site 2 were more likely to have cryptococcal antigenemia (aOR 5.49, 95% CI 1.57–19.16) led us to question the effect of geography on cryptococcus exposure and disease prevalence. The ecological habitat of Cryptococcus neoformans has been found to include rotting wood and trees (including eucalyptus) and in soil contaminated by bird guano [15,16]. Ethiopia has a large imported population of eucalyptus trees from Australia that could potentially serve as a source of infection. It is possible that patients attending site 1 as compared to site 2 had increased environmental exposure to C. neoformans; however, we did not collect detailed information on place of residence and it is also unclear if cryptococcal infection is from recent or past exposure to C. neoformans. Our intriguing finding generates more questions than answers and suggests that there may be hot spots for cryptococcal disease due to increased exposure or other yet unknown factors.

To assess the value of symptoms in detecting cryptococcal antigenemia we evaluated if the presence or absence of individual or combination of certain symptoms could predict or rule out cryptococcal antigenemia. This strategy has been used successfully in screening for TB in which the absence of current cough, fever, night sweats, and weight loss can reliably rule out TB among HIV infected patients in most RLS [17]. While persons who reported a fever were more likely to have cryptococcal antigenemia (aOR 2.95, 95% CI 1.26–6.87), 64% of positive patients reported no fever and 48% reported a lack of any symptoms. Additionally, we found non-optimal sensitivity, specificity, positive predictive value, and negative predictive value of any individual or combination of symptoms in detecting cryptococcal antigenemia. Our findings are similar to results from a prior study conducted in Uganda [9] and suggest that all adult HIV infected patients with low CD4 counts in high burdened settings should be tested for cryptococcal antigenemia regardless of symptoms.

The clinical relevance of cryptococcal screening has been established by studies that found a positive cryptococcal antigen test among ART naïve patients predicts the development of cryptococcal meningitis and is a strong risk factor for mortality [4,5,7]. Furthermore, Meya et al. demonstrated that pre-emptive therapy with fluconazole in asymptomatic cryptococcal antigen positive patients was a cost effective intervention. They found that 2–4 weeks of fluconazole (200–400 mg) along with ART initiation resulted in a 30-month survival of 71%. Additionally they calculated the cost to save one life using a test and treat strategy was $266 (with a cryptococcal antigenemia prevalence of 8.8%) [8]. The development of the cryptococcal antigen lateral flow assay (LFA) (Immy Inc, Norman, Oklahoma) has dramatically lowered Meya’s estimated cost to save one life to $39.70 [3] and made the widespread roll out of cryptococcal antigen screening a more realistic goal. The cryptococcal antigen LFA is a FDA approved rapid point of care diagnostic test that is highly sensitive, affordable (~$2), easy to perform and requires minimal infrastructure [14]. It has the potential to begin a new era of cryptococcal management in RLS. While cryptococcal screening and pre-emptive therapy appear to be cost effective interventions there remains many unanswered questions including the benefit of screening among ART experienced patients, how often to perform screening, and the optimal pre-emptive treatment regimen and duration.

Our study is subject to several limitations. These include lack of HIV viral load testing among patients enrolled in the study, which would have helped assess whether those on ART who had a positive diagnostic test for cryptococcal antigenemia were not controlled on their current ART regimen. Viral load testing is not routinely performed at the clinics where our study took place or in most HIV clinics in SSA. There was also an absence of lumbar punctures, which would help define the proportion of patients with cryptococcal meningitis among those with a positive cryptococcal
antigen test, and no long-term clinical follow up of our patient cohort. The decision to perform lumbar puncture was left up to the treating physician and none were performed. Future studies will assess the rates of meningitis and clinical outcomes among those with a positive cryptococcal antigen. Finally, our study took place at only two HIV clinics in Addis Ababa; therefore further investigations are needed at HIV clinics in Ethiopia outside Addis Ababa to assess the prevalence of cryptococcal infection in areas throughout the country.

In conclusion, we found a previously unreported high prevalence of cryptococcal antigenemia among HIV-infected patients with CD counts ≤200 cells/μl, including those on ART in Ethiopia. Additional important findings include no utility of symptom screening in disease detection and differential risk of disease based on location. The results of the present study indicate the need to scale up cryptococcal antigen screening among HIV-infected persons in Ethiopia and suggest it may be beneficial to expand current cryptococcal screening recommendations. In addition, further exploration of the effect of location and environment on the risk of cryptococcal infection is warranted.

**Author Contributions**

Conceived and designed the experiments: ASA RRK AT HMB NB DF AA. Performed the experiments: ASA AT. Analyzed the data: ASA RRK AT CS. Contributed reagents/materials/analysis tools: AA. Wrote the paper: ASA RRK CS AT HMB AA.

**References**

1. WHO (2011) Rapid Advice: Diagnosis, Prevention and Management of Cryptococcal Disease in HIV-infected Adults, Adolescents and Children. Geneva, World Health Organization.

2. Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, et al. (2009) Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 23: 525–530.

3. Rajasingham R, Meya DB, Boulware DR (2012) Integrating cryptococcal antigen screening and pre-emptive treatment into routine HIV care. J Acquir Immune Defic Syndr 59: e85–91.

4. Jarvis JN, Law SD, Vogt M, Bangani N, Wood R, et al. (2009) Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa. Clin Infect Dis 48: 856–862.

5. Liechty CA, Solberg P, Were W, Elsavu JP, Ransom RL, et al. (2007) Asymptomatic serum cryptococcal antigenemia and early mortality during antiretroviral therapy in rural Uganda. Trop Med Int Health 12: 929–935.

6. Micol R, Lortholary O, Sar B, Laureillard D, Ngath C, et al. (2007) Prevalence, determinants of positivity, and clinical utility of cryptococcal antigenemia in Cambodian HIV-infected patients. J Acquir Immune Defic Syndr 45: 555–559.

7. Pongsai P, Atamasirikul K, Sungkanuparph S (2010) The role of serum cryptococcal antigen screening for the early diagnosis of cryptococcosis in HIV-infected patients with different ranges of CD4 cell counts. J Infect 60: 474–477.

8. Meya DR, Monnabe YC, Castellanosov B, Cook BA, Elhizer AM, et al. (2010) Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4 cell count < or = 100 cells/μl, who start HIV therapy in resource-limited settings. Clin Infect Dis 51: 440–455.

9. French N, Gray K, Watera C, Nakyingi J, Lugadza E, et al. (2002) Cryptococcal infection in a cohort of HIV-1-infected Ugandan adults. AIDS 16: 1051–1038.

10. Federal Ministry of Health (2010) Report on progress towards implementation of the UN Declaration of Commitment on HIV/AIDS. Addis Ababa: Federal HIV/AIDS Prevention and Control Office.

11. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, et al. (2009) Research electronic data capture (REDCap) – a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 42: 377–381.

12. Hounet DW, Lemeshow S (2000) Applied logistic regression. 2nd ed. New York: Wiley.

13. Jarvis JN, Percival A, Bauman S, Pelfrey J, Meintjes G, et al. (2011) Evaluation of a novel point-of-care cryptococcal antigen test on serum, plasma, and urine from patients with HIV-associated cryptococcal meningitis. Clin Infect Dis 53: 1019–1023.

14. Lindley MD, Mekha N, Baggett HC, Sunthong Y, Aumtheinsichai R, et al. (2011) Evaluation of a newly developed lateral flow immunoassay for the diagnosis of cryptococcosis. Clin Infect Dis 53: 921–925.

15. Chowdhary A, Rhandhawa HS, Prakash A, Meis JF (2012) Environmental prevalence of Cryptococcus neoformans and Cryptococcus gattii in India: an update. Crit Rev Microbiol 39: 1–16.

16. Ellis DH, Pfeiffer TJ (1990) Ecology, life cycle, and infectious propagule of Cryptococcus neoformans and Cryptococcus gattii. Lancet 336: 923–925.

17. Getahun H, Kitiakraisak W, Helig CM, Corbet EL, Ayles H, et al. (2011) Development of a standardized screening rule for tuberculosis in people living with HIV in resource-limited settings: individual participant data meta-analysis of observational studies. PLoS Med 8: e1000391.